E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 1.8 SEK 3.45% Market Closed
Market Cap: 436.9m SEK
Have any thoughts about
Enzymatica AB (publ)?
Write Note

Enzymatica AB (publ)
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Enzymatica AB (publ)
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
E
Enzymatica AB (publ)
STO:ENZY
Total Liabilities
kr22.5m
CAGR 3-Years
-17%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Calliditas Therapeutics AB
STO:CALTX
Total Liabilities
kr1.6B
CAGR 3-Years
85%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Total Liabilities
kr454.2m
CAGR 3-Years
28%
CAGR 5-Years
25%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Total Liabilities
kr2.4B
CAGR 3-Years
77%
CAGR 5-Years
152%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Total Liabilities
kr24m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Total Liabilities
kr26.7m
CAGR 3-Years
18%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Enzymatica AB (publ)
Glance View

Market Cap
436.9m SEK
Industry
Pharmaceuticals

Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.

ENZY Intrinsic Value
1.83 SEK
Undervaluation 2%
Intrinsic Value
Price
E

See Also

What is Enzymatica AB (publ)'s Total Liabilities?
Total Liabilities
22.5m SEK

Based on the financial report for Sep 30, 2024, Enzymatica AB (publ)'s Total Liabilities amounts to 22.5m SEK.

What is Enzymatica AB (publ)'s Total Liabilities growth rate?
Total Liabilities CAGR 10Y
9%

Over the last year, the Total Liabilities growth was -53%. The average annual Total Liabilities growth rates for Enzymatica AB (publ) have been -17% over the past three years , -1% over the past five years , and 9% over the past ten years .

Back to Top